JPH02500880A - Nanbvの診断用薬およびワクチン - Google Patents
Nanbvの診断用薬およびワクチンInfo
- Publication number
- JPH02500880A JPH02500880A JP89500565A JP50056589A JPH02500880A JP H02500880 A JPH02500880 A JP H02500880A JP 89500565 A JP89500565 A JP 89500565A JP 50056589 A JP50056589 A JP 50056589A JP H02500880 A JPH02500880 A JP H02500880A
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- cdna
- clone
- sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims description 42
- 239000000032 diagnostic agent Substances 0.000 title description 5
- 229940039227 diagnostic agent Drugs 0.000 title description 5
- 239000002299 complementary DNA Substances 0.000 claims description 381
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 314
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 304
- 229920001184 polypeptide Polymers 0.000 claims description 296
- 238000000034 method Methods 0.000 claims description 257
- 239000000523 sample Substances 0.000 claims description 220
- 239000000427 antigen Substances 0.000 claims description 124
- 210000004027 cell Anatomy 0.000 claims description 116
- 125000003729 nucleotide group Chemical group 0.000 claims description 112
- 239000002773 nucleotide Substances 0.000 claims description 110
- 108091007433 antigens Proteins 0.000 claims description 107
- 102000036639 antigens Human genes 0.000 claims description 107
- 102000040430 polynucleotide Human genes 0.000 claims description 93
- 108091033319 polynucleotide Proteins 0.000 claims description 93
- 239000002157 polynucleotide Substances 0.000 claims description 93
- 150000007523 nucleic acids Chemical class 0.000 claims description 66
- 102000039446 nucleic acids Human genes 0.000 claims description 62
- 108020004707 nucleic acids Proteins 0.000 claims description 62
- 239000002245 particle Substances 0.000 claims description 57
- 150000001413 amino acids Chemical group 0.000 claims description 56
- 208000015181 infectious disease Diseases 0.000 claims description 51
- 239000013598 vector Substances 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 35
- 230000004927 fusion Effects 0.000 claims description 34
- 210000004185 liver Anatomy 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 28
- 230000002163 immunogen Effects 0.000 claims description 26
- 238000003018 immunoassay Methods 0.000 claims description 20
- 239000012678 infectious agent Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 230000002238 attenuated effect Effects 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 238000003259 recombinant expression Methods 0.000 claims description 7
- 230000009466 transformation Effects 0.000 claims description 7
- -1 HCV nucleic acid Chemical class 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 241000255925 Diptera Species 0.000 claims description 3
- 210000002308 embryonic cell Anatomy 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims 2
- 108020004414 DNA Proteins 0.000 description 107
- 241000700605 Viruses Species 0.000 description 107
- 210000002966 serum Anatomy 0.000 description 98
- 108090000623 proteins and genes Proteins 0.000 description 70
- 230000003612 virological effect Effects 0.000 description 65
- 235000001014 amino acid Nutrition 0.000 description 57
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 56
- 239000013615 primer Substances 0.000 description 56
- 210000004369 blood Anatomy 0.000 description 53
- 239000008280 blood Substances 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 49
- 239000012634 fragment Substances 0.000 description 47
- 238000009396 hybridization Methods 0.000 description 46
- 241000700721 Hepatitis B virus Species 0.000 description 40
- 108700026244 Open Reading Frames Proteins 0.000 description 40
- 241000282579 Pan Species 0.000 description 39
- 241000282577 Pan troglodytes Species 0.000 description 39
- 210000002381 plasma Anatomy 0.000 description 37
- 239000000243 solution Substances 0.000 description 37
- 238000012216 screening Methods 0.000 description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 description 32
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- 229940088598 enzyme Drugs 0.000 description 31
- 108020004635 Complementary DNA Proteins 0.000 description 29
- 238000002965 ELISA Methods 0.000 description 29
- 238000002955 isolation Methods 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- 102000004190 Enzymes Human genes 0.000 description 26
- 108090000790 Enzymes Proteins 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 26
- 238000009739 binding Methods 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 230000027455 binding Effects 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 23
- 239000000872 buffer Substances 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 23
- 239000002131 composite material Substances 0.000 description 22
- 230000009257 reactivity Effects 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 240000005893 Pteridium aquilinum Species 0.000 description 20
- 235000009936 Pteridium aquilinum Nutrition 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 239000011324 bead Substances 0.000 description 19
- 241000710831 Flavivirus Species 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 238000013519 translation Methods 0.000 description 17
- 238000011144 upstream manufacturing Methods 0.000 description 17
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- 229940098773 bovine serum albumin Drugs 0.000 description 16
- 239000008188 pellet Substances 0.000 description 16
- 238000003127 radioimmunoassay Methods 0.000 description 16
- 102000019197 Superoxide Dismutase Human genes 0.000 description 15
- 108010012715 Superoxide dismutase Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 208000006454 hepatitis Diseases 0.000 description 15
- 231100000283 hepatitis Toxicity 0.000 description 15
- 230000001900 immune effect Effects 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 241000709721 Hepatovirus A Species 0.000 description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
- 238000005119 centrifugation Methods 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 230000010076 replication Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 241000282412 Homo Species 0.000 description 11
- 239000000020 Nitrocellulose Substances 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000003443 antiviral agent Substances 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 229920001220 nitrocellulos Polymers 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 108091036078 conserved sequence Proteins 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 9
- 102100034343 Integrase Human genes 0.000 description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 210000004962 mammalian cell Anatomy 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- 229910052727 yttrium Inorganic materials 0.000 description 8
- 208000001490 Dengue Diseases 0.000 description 7
- 206010012310 Dengue fever Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 208000025729 dengue disease Diseases 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 101710172711 Structural protein Proteins 0.000 description 6
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 241000724709 Hepatitis delta virus Species 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 241001533590 Junonia Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 241000710924 Togaviridae Species 0.000 description 4
- 208000003152 Yellow Fever Diseases 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000003302 anti-idiotype Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108091028026 C-DNA Proteins 0.000 description 3
- 241000282994 Cervidae Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 208000037262 Hepatitis delta Diseases 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000029570 hepatitis D virus infection Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000709744 Enterobacterio phage MS2 Species 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 101710145006 Lysis protein Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 241000287462 Phalacrocorax carbo Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 244000047670 Viola x wittrockiana Species 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000012817 gel-diffusion technique Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 210000005238 principal cell Anatomy 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940102127 rubidium chloride Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- NMQPIBPZSLMCFI-UHFFFAOYSA-N 2-(4-methylphenyl)acetamide Chemical compound CC1=CC=C(CC(N)=O)C=C1 NMQPIBPZSLMCFI-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1s,2s,3r,4s)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000009881 Aega Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 101100322085 Arabidopsis thaliana CAC3 gene Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 102100033891 Arylsulfatase I Human genes 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100439299 Caenorhabditis elegans cgt-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 244000111056 Chinese albizia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001327708 Coriaria sarmentosa Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 102100036873 Cyclin-I Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000865049 Dermacentor parumapertus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000925544 Homo sapiens Arylsulfatase I Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000713124 Homo sapiens Cyclin-I Proteins 0.000 description 1
- 101100079846 Homo sapiens NEU1 gene Proteins 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101710128560 Initiator protein NS1 Proteins 0.000 description 1
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 101710144127 Non-structural protein 1 Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000220221 Rosales Species 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 101100514477 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSI1 gene Proteins 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100028760 Sialidase-1 Human genes 0.000 description 1
- 101150005400 Sobp gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 101000956368 Trittame loki CRISP/Allergen/PR-1 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067674 Viral Nonstructural Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011276 addition treatment Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003618 borate buffered saline Substances 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- FROBCXTULYFHEJ-OAHLLOKOSA-N propaquizafop Chemical compound C1=CC(O[C@H](C)C(=O)OCCON=C(C)C)=CC=C1OC1=CN=C(C=C(Cl)C=C2)C2=N1 FROBCXTULYFHEJ-OAHLLOKOSA-N 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091006091 regulatory enzymes Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- ALNUHUMOGUVHIO-XXJNWDAFSA-M sodium;7-[(1r,2s)-2-hexyl-5-hydroxycyclopentyl]heptanoate Chemical compound [Na+].CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC([O-])=O ALNUHUMOGUVHIO-XXJNWDAFSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000004577 thatch Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000007919 viral pathogenicity Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims (40)
- 1.精製されたHCVポリヌクレオチド。
- 2.組換えHCVポリヌクレオチド。
- 3.HCVゲノムまたはHCV cDNAに由来する配列を有する組換えHCV ポリヌクレオチド。
- 4.HCVのエピトープをコードする組換えポリヌクレオチド。
- 5.請求の範囲第2項,第3項,または第4項のポリヌクレオチドを含む組換え ベクター。
- 6.請求の範囲第5項のベクターで形質転換された宿主細胞。
- 7.HCVゲノムまたはHCV cDNAに由来するDHAのオープンリーディ ングフレーム(ORF)を有する組換え発現系であって,該ORFが所望の宿主 と適合し得る制御配列に対して作動可能なように連結されている,組換え発現系 。
- 8.請求の範囲第7項の組換え発現系で形質転換させた細胞。
- 9.請求の範囲第8項の細胞により生産されたポリペプチド。
- 10.精製されたHCV。
- 11.請求の範囲第10項のHCVに由来するポリペプチドの調製物。
- 12.精製されたHCVポリペプチド。
- 13.HCVに含まれるエピトープと免疫学的に同一であるとみなし得るエピト ープを有する精製されたポリペプチド。
- 14.組換えHCV ポリペプチド。
- 15.HCV ゲノムまたはHCV cDNAに由来する配列を有する組換えポ リペプチド。
- 16.HCV エピトープを有する組換えポリペプチド。
- 17.HCV ポリペプチドを有する融合ポリペプチド。
- 18.HCV エピトープに対するモノクローナル抗体。
- 19.HCV に対するポリクローナル抗体の精製された調製物。
- 20.BCV 感染に対して免疫原性の粒子であって,真核生物宿主内で生産さ れる場合に粒子を形成し得るアミノ酸配列を有する非HCV ポリペプチドと, HCV エピトープとを有する粒子。
- 21.HCV に対するポリヌクレオチドプローブ。
- 22.HCV に由来するポリヌクレオチドの存在について試料を分析するため のキットであって,適当な容器内に,約8個またはそれ以上のヌクレオチドから なるHCV 由来のヌクレオチド配列を含むポリヌクレオチドプローブを有する キット。
- 23.HCV 抗原の存在について試料を分析するためのキットであって,適当 な容器内に,検出されるべきHCV 抗原に対する抗体を有するキット。
- 24.HCV 抗原に対する抗体の存在について試料を分析するためのキットで あって,適当な容器内に,HCV 抗原に存在するHCV エピトープを含むポ リペプチドを有するキット。
- 25.固体担体に付着させた,HCV エピトープを有するポリペプチド。
- 26.固体担体に付着させた,HCV エピトープに対する抗体。
- 27.HCV エピトープを含むポリペプチドを生産する方法であって,HCV エピトープを含むポリペプチドをコードする配列を含む発現ベクターで形質転 換させた宿主細胞を,該ポリペプチドを発現する条件下でインキュベートするこ と,を包含する生産方法。
- 28.請求の範囲第27項の方法により生産された,HCV エピトープを含む ポリペプチド。
- 29.試料中のHCV 核酸を検出する方法であって,(a)該試料の核酸を, HCV ポリヌクレオチドに対するプローブと,該プローブと該試料由来のHC V 核酸との間にポリヌクレオチド二本鎖を形成する条件下で反応させること; および(b)該プローブを含むポリヌクレオチド二本鎖を検出すること, を包含する検出方法。
- 30.HCV 抗原を検出するための免疫学的検定法であって,(a)HCV 抗原を含んでいる疑いのある試料を,検出されるべきHCV 抗原に対するプロ ーブ抗体と共に,抗原−抗体複合体を形成する条件下でインキュベートすること ;および(b)該プローブ抗体を含む抗原−抗体複合体を検出すること,を包含 する免疫学的検定法。
- 31.HCV 抗原に対する抗体を検出するための免疫学的検定法であって, (a)抗HCV 抗体を含んでいる疑いのある試料を,HCV のエピトープを 含むプローブポリヌクレオチドと共に,抗体−抗原複合体を形成する条件下でイ ンキュベートすること;および(b)該プローブ抗原を含む抗体−抗原複合体を 検出すること,を包含する免疫学的検定法。
- 32.HCV 感染を処置するためのワクチンであって,HCV エピトープを 含む免疫原性ポリペプチドを含有し,該免疫原性ポリペプチドが薬学的に容認し 得る賦形剤中に,薬学的に効果的な用量で存在する,ワクチン。
- 33.HCV 感染を処置するためのワクチンであって,薬学的に容認される賦 形剤中に,薬学的に効果的な用量で,不活性化されたHCV を含有するワクチ ン。
- 34.HCV 感染を処置するためのワクチンであって,薬学的に容認される賦 形剤中に,薬学的に効果的な用量で,弱毒化されたHCV を含有するワクチン 。
- 35.HCV に感染した組織培養増殖細胞。
- 36.請求の範囲第35項に記載のHCV 感染細胞であって,該細胞は,ヒト のマクロファージ細胞系,肝細胞系,カの細胞系,ダニの細胞系,マウスのマク ロファージ細胞系,または胚細胞である。
- 37.請求の範囲第35項に記載のHCV 感染細胞であって,該細胞は,HC V 感染個体の肝臓に由来する細胞系である。
- 38.HCV に対する抗体を生産する方法であって,HCV エピトープを含 む単離された免疫原性ポリペプチドを,免疫応答を生ずるのに充分な量で個体に 投与することを包含する生産方法。
- 39.HCV に対する抗体を生産する方法であって,請求の範囲第11項に記 載のポリペプチド調製物を個体に投与することを包含し,該調製物が少なくとも 1つの免疫原性ポリペプチドを含有し,かつ該投与が免疫応答を生ずるのに充分 な量で行われる,生産方法。
- 40.未確認の感染因子のゲノムに由来するcDNAを単離する方法であって, 該方法は以下の工程を包含する:(a)該感染因子に感染した組織から単離され た核酸から調製されたcDNAライブラリーを含む発現ベクターで形質転換させ た宿主細胞を用意し,該cDNAにコードされたポリペプチドを発現する条件下 で該宿主細胞を増殖させること;(b)該cDNAの発現産物を,該感染因子に 感染した個体の抗体含有身体構成部分と,免疫反応を起こす条件下で反応させ, その結果として形成される抗体−抗原複合体を検出すること;(c)該工程(b )の抗体−抗原複合体を形成するポリペプチドを発現する宿主細胞を,個々のク ローンとして増殖する条件下で増殖させ,該クローンを単離すること;(d)該 工程(c)のクローン由来の細胞を,該cDNA内にコードされたポリペプチド を発現する条件下で増殖させ,該発現産物を,該工程(a)の個体以外の個体で あって該感染因子に感染している個体の抗体含有身体構成部分,および該感染因 子に感染していない対照個体と反応させ,その結果として形成される抗体−抗原 複合体を検出すること; (e)感染した個体および感染している疑いのある個体の抗体含有身体構成部分 から抗体−抗原複合体を形成するが,対照個体の該部分からは抗体−抗原複合体 を形成しないポリペプチドを発現する宿主細胞を,個々のクローンとして増殖す る条件下で増殖させ,該クローンを単離すること;および(f)該工程(e)の 宿主細胞クローンからcDNAを単離すること。
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12271487A | 1987-11-18 | 1987-11-18 | |
US13988687A | 1987-12-30 | 1987-12-30 | |
US16107288A | 1988-02-26 | 1988-02-26 | |
US19126388A | 1988-05-06 | 1988-05-06 | |
US26358488A | 1988-10-26 | 1988-10-26 | |
US27145088A | 1988-11-14 | 1988-11-14 | |
US161072 | 1988-11-14 | ||
US263,584 | 1988-11-14 | ||
US271,450 | 1988-11-14 | ||
US122,714 | 1988-11-14 | ||
US191263 | 1988-11-14 | ||
US139,886 | 1988-11-14 |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4361785A Division JP2662350B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬 |
JP4361784A Division JP2809956B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬 |
JP4361787A Division JP2662351B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬およびワクチン |
JP4361786A Division JP2532805B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬およびワクチン |
JP5178446A Division JP2662358B2 (ja) | 1987-11-18 | 1993-06-11 | Nanbvの診断用薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02500880A true JPH02500880A (ja) | 1990-03-29 |
JPH0581600B1 JPH0581600B1 (ja) | 1993-11-15 |
Family
ID=27557988
Family Applications (16)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP89500565A Expired - Lifetime JPH02500880A (ja) | 1987-11-18 | 1988-11-18 | Nanbvの診断用薬およびワクチン |
JP4361784A Expired - Lifetime JP2809956B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬 |
JP4361785A Expired - Lifetime JP2662350B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬 |
JP4361787A Expired - Lifetime JP2662351B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬およびワクチン |
JP4361786A Expired - Lifetime JP2532805B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬およびワクチン |
JP5178446A Expired - Lifetime JP2662358B2 (ja) | 1987-11-18 | 1993-06-11 | Nanbvの診断用薬 |
JP8239921A Expired - Lifetime JP2810022B2 (ja) | 1987-11-18 | 1996-08-21 | Nanbvの診断用薬 |
JP24145196A Expired - Lifetime JP3171793B2 (ja) | 1987-11-18 | 1996-08-22 | Nanbvの診断用薬 |
JP9099651A Expired - Lifetime JP2810032B2 (ja) | 1987-11-18 | 1997-04-01 | Nanbvの診断用薬 |
JP10111631A Pending JPH10290696A (ja) | 1987-11-18 | 1998-04-06 | Nanbvの診断用薬およびワクチン |
JP10111632A Pending JPH10290697A (ja) | 1987-11-18 | 1998-04-06 | Nanbvの培養法 |
JP11157193A Pending JP2000023683A (ja) | 1987-11-18 | 1999-06-03 | Nanbvの診断用薬 |
JP2005325483A Withdrawn JP2006104207A (ja) | 1987-11-18 | 2005-11-09 | Nanbvの診断用薬 |
JP2005325486A Withdrawn JP2006117681A (ja) | 1987-11-18 | 2005-11-09 | Nanbvの診断用薬およびワクチン |
JP2007095590A Pending JP2007197456A (ja) | 1987-11-18 | 2007-03-30 | Nanbvの診断用薬 |
JP2007179093A Pending JP2008007508A (ja) | 1987-11-18 | 2007-07-06 | Nanbvの診断用薬およびワクチン |
Family Applications After (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4361784A Expired - Lifetime JP2809956B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬 |
JP4361785A Expired - Lifetime JP2662350B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬 |
JP4361787A Expired - Lifetime JP2662351B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬およびワクチン |
JP4361786A Expired - Lifetime JP2532805B2 (ja) | 1987-11-18 | 1992-12-16 | Nanbvの診断用薬およびワクチン |
JP5178446A Expired - Lifetime JP2662358B2 (ja) | 1987-11-18 | 1993-06-11 | Nanbvの診断用薬 |
JP8239921A Expired - Lifetime JP2810022B2 (ja) | 1987-11-18 | 1996-08-21 | Nanbvの診断用薬 |
JP24145196A Expired - Lifetime JP3171793B2 (ja) | 1987-11-18 | 1996-08-22 | Nanbvの診断用薬 |
JP9099651A Expired - Lifetime JP2810032B2 (ja) | 1987-11-18 | 1997-04-01 | Nanbvの診断用薬 |
JP10111631A Pending JPH10290696A (ja) | 1987-11-18 | 1998-04-06 | Nanbvの診断用薬およびワクチン |
JP10111632A Pending JPH10290697A (ja) | 1987-11-18 | 1998-04-06 | Nanbvの培養法 |
JP11157193A Pending JP2000023683A (ja) | 1987-11-18 | 1999-06-03 | Nanbvの診断用薬 |
JP2005325483A Withdrawn JP2006104207A (ja) | 1987-11-18 | 2005-11-09 | Nanbvの診断用薬 |
JP2005325486A Withdrawn JP2006117681A (ja) | 1987-11-18 | 2005-11-09 | Nanbvの診断用薬およびワクチン |
JP2007095590A Pending JP2007197456A (ja) | 1987-11-18 | 2007-03-30 | Nanbvの診断用薬 |
JP2007179093A Pending JP2008007508A (ja) | 1987-11-18 | 2007-07-06 | Nanbvの診断用薬およびワクチン |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0318216B2 (ja) |
JP (16) | JPH02500880A (ja) |
KR (2) | KR0138776B1 (ja) |
CN (5) | CN1074422C (ja) |
BR (1) | BR8807310A (ja) |
CA (1) | CA1341629C (ja) |
DE (2) | DE318216T1 (ja) |
ES (1) | ES2012739T5 (ja) |
FI (3) | FI105652B (ja) |
GR (1) | GR900300069T1 (ja) |
HK (3) | HK38293A (ja) |
HU (3) | HU220204B (ja) |
IE (1) | IE62868B1 (ja) |
LV (1) | LV10726B (ja) |
NO (1) | NO304990B1 (ja) |
NZ (1) | NZ227011A (ja) |
UA (1) | UA42668C2 (ja) |
WO (1) | WO1989004669A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03139282A (ja) * | 1988-09-30 | 1991-06-13 | Handai Biseibutsubiyou Kenkyukai | 非a非b肝炎患者の血清と抗原抗体反応するペプチド、及び該ペプチドをコードするdna |
WO1991019744A1 (en) * | 1990-06-12 | 1991-12-26 | Japan As Represented By Director General Of Agency Of National Institute Of Health | Hepatitis c virus antigen polypeptide, production thereof, and detection of antibody |
WO1992001714A1 (en) * | 1990-07-24 | 1992-02-06 | Yamanouchi Pharmaceutical Co., Ltd. | Non-a non-b hepatitis virus antigen |
WO1992009634A1 (en) * | 1990-11-29 | 1992-06-11 | Toray Industries, Incorporated | Non-a non-b hepatitis virus antigen protein |
WO1992018532A1 (en) * | 1991-04-17 | 1992-10-29 | Eisai Co., Ltd. | Rna, dna and virus antigen protein of non-a non-b hepatitis virus |
JPH06153959A (ja) * | 1992-10-16 | 1994-06-03 | Evernew Biotec Inc | C型肝炎ウィルスの非構造タンパク質及びそれを用いての診断方法及びキット |
EP0717104A2 (en) | 1994-07-12 | 1996-06-19 | The Tokyo Metropolitan Institute Of Medical Science | Immunoassay of non-A, non-B hepatitis virus-related antigens, monoclonal antibodies for use therein, and hybridomas producing the antibodies |
US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
US5712088A (en) * | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
US5714596A (en) * | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
JP2733138B2 (ja) * | 1990-04-04 | 1998-03-30 | カイロン コーポレイション | 抗hcv抗体の免疫アッセイに使用するc型肝炎ウイルス(hcv)抗原の組合せ |
US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
US6171782B1 (en) | 1987-11-18 | 2001-01-09 | Chiron Corporation | Antibody compositions to HCV and uses thereof |
US6861212B1 (en) | 1987-11-18 | 2005-03-01 | Chiron Corporation | NANBV diagnostics and vaccines |
Families Citing this family (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1074422C (zh) * | 1987-11-18 | 2001-11-07 | 希龙股份有限公司 | 制备含有hcv表位的分离多肽的方法 |
US5683864A (en) * | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
AU650038B2 (en) * | 1988-03-11 | 1994-06-09 | Abbott Laboratories | CKS method of protein synthesis |
US5191064A (en) * | 1988-09-30 | 1993-03-02 | The Research Foundation For Microbial Diseases (Osaka University) | Non-a, non-b hepatitis virus antigen peptide |
JPH02167081A (ja) * | 1988-12-21 | 1990-06-27 | Tetsuo Nakamura | 非A非B型肝炎ウイルスゲノムRNA、cDNAおよびウイルス抗原蛋白質 |
HU225068B1 (en) * | 1989-03-17 | 2006-05-29 | Chiron Corp | Process for producing diagnostics and vaccine of nanbh |
MC2188A1 (fr) * | 1989-05-18 | 1992-09-16 | Chiron Corp | Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c |
JPH0330676A (ja) * | 1989-06-28 | 1991-02-08 | Sanwa Kagaku Kenkyusho Co Ltd | 非a非b型肝炎ウイルスのdna、そのクローン及びこれらの調製法 |
EP0416725A3 (en) * | 1989-07-14 | 1991-03-20 | Chugai Seiyaku Kabushiki Kaisha | Blood-borne non-a, non-b hepatitis specific protein, dna encoding it, and process for its production |
ES2110411T3 (es) * | 1989-08-25 | 1998-02-16 | Chiron Corp | Metodos para cultivar el virus de la hepatitis c (hcv) en lineas celulares de linfocitos b o t. |
CA2065287C (en) * | 1989-09-15 | 1999-12-21 | Tatsuo Miyamura | New hcv isolates |
US5372928A (en) * | 1989-09-15 | 1994-12-13 | Chiron Corporation | Hepatitis C virus isolates |
FR2654113A1 (fr) * | 1989-11-09 | 1991-05-10 | Pasteur Institut | Procede de diagnostic de virus appartenant a la famille des flaviviridae. |
ES2029171A6 (es) * | 1989-12-18 | 1992-07-16 | Wellcome Found | Un procedimiento para preparar un polipeptido virico de hepatitis no a y no b post-transfusional (pt-nanbh) |
US7166287B1 (en) | 1989-12-18 | 2007-01-23 | Glaxo Wellcome Inc. | Viral agent |
AU638304B2 (en) * | 1989-12-22 | 1993-06-24 | Abbott Laboratories | Hepatitis c assay |
US5308750A (en) * | 1989-12-22 | 1994-05-03 | Abbott Laboratories | Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same |
EP0435229A1 (en) * | 1989-12-27 | 1991-07-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | DNA of non-A, non-B hepatitis virus gene, its clone and use thereof |
CA2036022A1 (en) * | 1990-02-09 | 1991-08-10 | Tetsuo Nakamura | Non-a, non-b hepatitis related nucleic acids, antigens, antibodies and their detection reagents |
US5747239A (en) * | 1990-02-16 | 1998-05-05 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines |
US5106726A (en) * | 1990-02-16 | 1992-04-21 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV |
KR940000755B1 (ko) * | 1990-02-16 | 1994-01-29 | 유나이티드 바이오메디칼 인코오포레이티드 | Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드 |
US5582968A (en) * | 1990-02-16 | 1996-12-10 | United Biomedical, Inc. | Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis |
US5639594A (en) * | 1990-02-16 | 1997-06-17 | United Biomedical, Inc. | Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis |
EP0445801A3 (en) * | 1990-03-08 | 1992-07-01 | Kuraray Co., Ltd. | Peptide and its use |
EP0447984A1 (en) * | 1990-03-20 | 1991-09-25 | Abbott Laboratories | Hyperimmune globulin against hepatitis C virus and method for making same |
WO1991014779A1 (en) * | 1990-03-28 | 1991-10-03 | Mitsui Toatsu Chemicals, Incorporated | Diagnostic for hepatitis virus |
JPH0436185A (ja) * | 1990-03-28 | 1992-02-06 | Kyowa Hakko Kogyo Co Ltd | 融合抗原ポリペプチド |
US5371017A (en) * | 1990-04-04 | 1994-12-06 | Chiron Corporation | Hepatitis C virus protease |
US5712087A (en) * | 1990-04-04 | 1998-01-27 | Chiron Corporation | Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens |
US6194140B1 (en) | 1990-04-04 | 2001-02-27 | Chiron Corporation | HCV NS3 protein fragments having helicase activity and improved solubility |
EP1018558A3 (en) * | 1990-04-06 | 2002-06-05 | Genelabs Technologies, Inc. | Hepatitis C Virus Epitopes |
EP0461863A1 (en) * | 1990-06-12 | 1991-12-18 | Immuno Japan Inc. | Oligonucleotide primers, and their application for high-fidelity detection of non-A, non-B hepatitis virus |
US5747339A (en) * | 1990-06-25 | 1998-05-05 | Research Foundation For Microbial Diseases Of Osaka | Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide |
EP0464287A1 (en) * | 1990-06-25 | 1992-01-08 | The Research Foundation for Microbial Diseases of Osaka University | Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide |
FI913068A (fi) * | 1990-06-25 | 1991-12-26 | Univ Osaka Res Found | Non-a-, non-b-hepatitisviruspartiklar. |
JPH05508318A (ja) * | 1990-06-30 | 1993-11-25 | アクゾ・エヌ・ヴエー | 非―a非―b配列 |
KR0181517B1 (ko) * | 1990-07-09 | 1999-04-01 | 나까하라 노부유끼 | 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도 |
ATE150086T1 (de) * | 1990-07-11 | 1997-03-15 | Shionogi & Co | Cdns-sequenz und detektion des hepatitis c-virus |
CA2047792C (en) * | 1990-07-26 | 2002-07-02 | Chang Y. Wang | Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines |
US6172189B1 (en) * | 1990-08-24 | 2001-01-09 | Abbott Laboratories | Hepatitis C assay utilizing recombinant antigens |
CA2049679C (en) * | 1990-08-24 | 2005-06-21 | Sushil G. Devare | Hepatitis c assay utilizing recombinant antigens |
US7863008B2 (en) | 1990-08-25 | 2011-01-04 | Bioprocess Pty Ltd. | Method for detecting NANBV associated seroconversion |
WO1992003458A1 (en) * | 1990-08-25 | 1992-03-05 | New York Blood Center | Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines |
JPH06502075A (ja) * | 1990-10-12 | 1994-03-10 | アボット・ラボラトリーズ | C型肝炎ウイルス抗体 |
JP3549201B2 (ja) * | 1990-10-24 | 2004-08-04 | 中外製薬株式会社 | 非a非b型肝炎特異的遺伝子の検出方法及び検出用試薬組成物 |
DE4120281C2 (de) * | 1991-06-19 | 1999-11-25 | Dade Behring Marburg Gmbh | Immunchemisches Verfahren zum gleichzeitigen Nachweis von mehreren verschiedenen Antikörperspezifitäten, Peptidmischungen und Test dazu |
DE4121431A1 (de) * | 1991-06-28 | 1993-01-07 | Behringwerke Ag | Synthetische core-peptide zur bestimmung von hcv-antikoerpern und hcv-antigenen, mittel dazu und ihre verwendung in diesen nachweis-verfahren |
DE59109221D1 (de) * | 1990-11-03 | 2001-11-15 | Dade Behring Marburg Gmbh | HCV-spezifische Peptide, Mittel dazu und ihre Verwendung |
DE4112743C2 (de) * | 1991-04-19 | 2000-01-13 | Dade Behring Marburg Gmbh | Synthetische Core-Peptide zur Bestimmung von HCV-Antikörpern und HCV-Antigenen, Mittel dazu und ihre Verwendung in diesen Nachweis-Verfahren |
DE4034982C2 (de) * | 1990-11-03 | 1999-12-23 | Dade Behring Marburg Gmbh | Synthetische Polypeptide zur Bestimmung von HCV-Antikörpern und HCV-Antigenen, Mittel dazu und ihre Verwendung in diesen Nachweis-Verfahren |
DE69131046T2 (de) * | 1990-11-07 | 1999-10-21 | Abbott Lab | Monoklonale antikörper gegen den hepatitis c-virus und verfahren diese zu benutzen |
US5753430A (en) * | 1990-11-07 | 1998-05-19 | Abbott Laboratories | Monoclonal antibodies to hepatitis C virus and method for using same |
US6274148B1 (en) | 1990-11-08 | 2001-08-14 | Chiron Corporation | Hepatitis C virus asialoglycoproteins |
CA2055149A1 (en) * | 1990-11-08 | 1992-05-09 | Hiroaki Okamoto | Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides |
SK286106B6 (sk) * | 1990-11-08 | 2008-03-05 | Novartis Vaccines & Diagnostics, Inc. | Spôsob vykonávania imunodiagnostickej skúšky na detekciu protilátky proti vírusu hepatitídy C |
DE69131316T2 (de) * | 1990-11-30 | 1999-11-11 | Japan Immuno Inc | Non-A, non-B hepatitisverwandte Nukleinsäuren, Antigene und Antikörper und ihre Feststellungsreagenzien |
US6007982A (en) * | 1990-12-14 | 1999-12-28 | Innogenetics N.V. | Synthetic antigens for the detection of antibodies to hepatitis C virus |
US5910404A (en) | 1990-12-14 | 1999-06-08 | Innogenetics N.V. | Synthetic antigens for the detection of antibodies to hepatitis C virus |
DE69029092T2 (de) * | 1990-12-14 | 1997-04-17 | Innogenetics Nv | Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus |
KR930703613A (ko) * | 1991-01-25 | 1993-11-30 | 챨스 엠. 브록 | 시료 희석물중 과산화물 디스뮤타제의 용도 |
DE69225960T2 (de) * | 1991-01-31 | 1999-01-21 | Abbott Lab | Monoklonale antikörper gegen mögliche hcv-hüllregionen und methoden diese zu benutzen |
DE69216333T2 (de) * | 1991-03-26 | 1997-07-10 | Dade Int Inc | Nicht-a, nicht-b hepatitis test |
US5574132A (en) * | 1991-04-05 | 1996-11-12 | Biochem Immunosystems Inc. | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) |
EP0516270A3 (en) * | 1991-04-10 | 1993-06-23 | Immuno Japan Inc. | Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides |
EP0510952A1 (en) * | 1991-04-26 | 1992-10-28 | Immuno Japan Inc. | Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus |
ES2207633T3 (es) * | 1991-05-08 | 2004-06-01 | Chiron Corporation | Secuencias genomicas del vhc para diagnostico y tratamiento. |
ES2040615B1 (es) * | 1991-05-27 | 1994-05-16 | Nebrda Fernando Javi Bartolome | Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis. |
FR2677372B1 (fr) * | 1991-06-06 | 1994-11-10 | Pasteur Institut | Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques. |
TW360711B (en) * | 1991-06-10 | 1999-06-11 | Lucky Ltd | CDNAs of Korean hepatitis C virus and polypeptides encoded thereby |
CA2070952A1 (en) * | 1991-06-11 | 1992-12-12 | Makoto Seki | Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same |
JP3516681B2 (ja) * | 1991-06-24 | 2004-04-05 | カイロン コーポレイション | C型肝炎ウイルス(hcv)ポリペプチド |
DE4209215A1 (de) | 1991-07-04 | 1993-01-07 | Boehringer Mannheim Gmbh | Hcv peptidantigene und verfahren zur bestimmung von hcv |
AU2492792A (en) * | 1991-08-21 | 1993-03-16 | Abbott Laboratories | Hepatitis c assay utilizing recombinant antigens from ns5 region |
AU2513592A (en) * | 1991-08-21 | 1993-03-16 | Abbott Laboratories | Hepatitis c assay utilizing recombinant antigens to ns1 |
DE69227776T2 (de) * | 1991-08-21 | 1999-07-01 | Abbott Lab | Monoklonale antikörper gegen mutmassliche hepatitis c-virus ns5-proteine und ihre anwendungsmethoden |
ES2198514T3 (es) * | 1991-08-27 | 2004-02-01 | F. Hoffmann-La Roche Ag | Cebadores y sondas para la deteccion de la hepatitis c. |
JPH06511149A (ja) * | 1991-09-13 | 1994-12-15 | カイロン コーポレイション | 免疫反応性c型肝炎ウイルスのポリペプチド組成物 |
ZA927837B (en) * | 1991-10-15 | 1994-03-11 | Akzo Nv | Monoclonal antibodiesto hepatitis C virus |
CA2099883A1 (en) * | 1991-11-07 | 1993-05-08 | John A. Kink | Epitope mapping of the c33c region of hcv |
JPH05130874A (ja) * | 1991-11-07 | 1993-05-28 | Sanwa Kagaku Kenkyusho Co Ltd | ヒトC型肝炎ウイルスのcDNA、そのクローン及びこれらの利用法 |
JP3688290B2 (ja) * | 1991-11-21 | 2005-08-24 | コモン サーヴィシス エージェンシー | C型肝炎ウイルス検査 |
DE69333269T2 (de) * | 1992-01-31 | 2004-07-29 | Abbott Laboratories, Abbott Park | Expressionssystem in säugetieren für hcv-proteine |
US6709828B1 (en) | 1992-03-06 | 2004-03-23 | N.V. Innogenetics S.A. | Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them |
US6667387B1 (en) | 1996-09-30 | 2003-12-23 | N.V. Innogenetics S.A. | HCV core peptides |
US6620414B2 (en) | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
MA22842A1 (fr) * | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
US5866139A (en) * | 1992-06-04 | 1999-02-02 | Institut Pasteur | Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications |
US5980899A (en) * | 1992-06-10 | 1999-11-09 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells |
UA39944C2 (uk) | 1992-07-07 | 2001-07-16 | Чірон Корпорейшн | Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі |
US5859230A (en) * | 1992-07-30 | 1999-01-12 | Genelabs Technologies, Inc. | Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof |
DE4240980A1 (de) * | 1992-08-07 | 1994-02-10 | Boehringer Mannheim Gmbh | HCV Peptidantigene und Verfahren zur Bestimmung von HCV |
DE69330372T2 (de) | 1992-09-10 | 2002-03-14 | Isis Pharmaceuticals Inc | ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN |
US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6995146B2 (en) | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
US5922857A (en) * | 1992-09-28 | 1999-07-13 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
CN1059928C (zh) * | 1992-09-29 | 2000-12-27 | 天津普生生物科技有限公司 | 利用大肠杆菌制备可用来检验c型肝炎之抗原蛋白的方法 |
EP0593291A3 (en) * | 1992-10-16 | 1995-03-15 | Evernew Biotech Inc | Non-structural protein of the hepatitis C virus, as well as diagnostic procedure and test kit. |
US6153378A (en) * | 1992-10-16 | 2000-11-28 | Bionova Corporation | Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus |
JP2778886B2 (ja) * | 1992-10-16 | 1998-07-23 | エバーニュー バイオテック インコーポレイティド | C型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット |
WO1994013700A1 (en) * | 1992-12-07 | 1994-06-23 | Akzo Nobel N.V. | Peptides from the c33 region of hcv, antibodies thereto and methods for the detection of hcv |
CA2151128A1 (en) * | 1992-12-07 | 1994-06-23 | Winand Johannes Antonius Habets | Hepatitis c virus (hcv) non-structural-3 peptides, antibodies thereto and methods for the detection of hcv |
WO1994024565A1 (en) * | 1993-04-22 | 1994-10-27 | Genelabs Technologies, Inc. | Hepatitis c virus immunodiagnostic antigens and antibodies |
US6762024B2 (en) * | 1993-04-27 | 2004-07-13 | Innogenetics, S.A. | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents |
JP3751315B2 (ja) | 1993-05-05 | 2006-03-01 | コモン サーヴィシス エージェンシー | C型肝炎ウイルス4、5及び6型 |
ES2232815T5 (es) | 1993-05-10 | 2009-06-15 | Novartis Vaccines And Diagnostics, Inc. | Metodos de tipado del virus de la hepatitis c y reactivos para usar en los mismos. |
EP0697888B1 (en) | 1993-05-12 | 2003-09-17 | Chiron Corporation | Conserved motif of hepatitis c virus e2/ns1 region |
US5885771A (en) * | 1993-10-29 | 1999-03-23 | Srl, Inc. | Antigenic peptide compound and immunoassay |
US5610009A (en) * | 1994-01-28 | 1997-03-11 | Abbott Laboratories | Mammalian expression systems for hepatitis C virus envelope genes |
US6051374A (en) * | 1994-02-14 | 2000-04-18 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use |
US5843450A (en) * | 1994-02-14 | 1998-12-01 | Abbott Laboratories | Hepatitis GB Virus synthetic peptides and uses thereof |
US6720166B2 (en) | 1994-02-14 | 2004-04-13 | Abbott Laboratories | Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use |
US6156495A (en) * | 1994-02-14 | 2000-12-05 | Abbott Laboratories | Hepatitis GB virus recombinant proteins and uses thereof |
US5981172A (en) * | 1994-02-14 | 1999-11-09 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E Hepatitis reagents and methods for their use |
US6558898B1 (en) | 1994-02-14 | 2003-05-06 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use |
US6451578B1 (en) | 1994-02-14 | 2002-09-17 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use |
US5874563A (en) * | 1994-05-20 | 1999-02-23 | Genelabs Technologies, Inc. | Hepatitis G virus and molecular cloning thereof |
US5824507A (en) * | 1994-05-20 | 1998-10-20 | Genelabs Technologies, Inc. | Hepatitis G virus and molecular cloning thereof |
WO1996004301A2 (en) * | 1994-07-29 | 1996-02-15 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
CA2195312A1 (en) | 1994-07-29 | 1996-02-15 | Mark Selby | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
DE4428705A1 (de) * | 1994-08-12 | 1996-02-15 | Boehringer Mannheim Gmbh | Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus |
US5955318A (en) * | 1995-08-14 | 1999-09-21 | Abbott Laboratories | Reagents and methods useful for controlling the translation of hepatitis GBV proteins |
US5807670A (en) * | 1995-08-14 | 1998-09-15 | Abbott Laboratories | Detection of hepatitis GB virus genotypes |
US5709997A (en) * | 1995-08-14 | 1998-01-20 | Abbott Laboratories | Nucleic acid detection of hepatitis GB virus |
US6127116A (en) * | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
GB9517926D0 (en) | 1995-09-01 | 1995-11-01 | Biocine Spa | Binding protein |
US5851758A (en) * | 1995-10-25 | 1998-12-22 | Childrens Research Institute | Cytopathic replication of hepatitis C virus in a new cell line |
US5837442A (en) | 1995-11-29 | 1998-11-17 | Roche Molecular Systems, Inc. | Oligonucleotide primers for amplifying HCV nucleic acid |
US5851759A (en) * | 1996-04-19 | 1998-12-22 | Chiron Corporation | Heteroduplex tracking assay (HTA) for genotyping HCV |
JP3715027B2 (ja) | 1996-05-07 | 2005-11-09 | シスメックス株式会社 | C型肝炎ウイルス感染症診断薬 |
CU22642A1 (es) * | 1996-12-12 | 2000-12-22 | Ct Ingenieria Genetica Biotech | Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso |
US7338759B1 (en) | 1997-03-04 | 2008-03-04 | Washington University | HCV variants |
US7049428B1 (en) | 1998-03-04 | 2006-05-23 | Washington University | HCV variants |
EP0980434B1 (en) | 1997-05-06 | 2009-07-29 | Novartis Vaccines and Diagnostics, Inc. | Intracellular production of hepatitis c e2 truncated polypeptid |
US6010848A (en) * | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
US6153392A (en) * | 1997-07-30 | 2000-11-28 | Bionova Corporation | Devices and methods comprising an HBcAg from hepatitis B virus |
ATE449847T1 (de) | 1997-10-06 | 2009-12-15 | Novartis Vaccines & Diagnostic | Hepatitis c rezeptorprotein cd81 |
BR9813930A (pt) | 1997-11-06 | 2006-12-19 | Chiron Spa | antìgeno neisserial |
DE69838513T2 (de) | 1997-12-11 | 2008-07-03 | Smithkline Beecham Corp. | Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren |
AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
EP2261347A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
CA2689696C (en) | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
JP2002537355A (ja) | 1999-02-26 | 2002-11-05 | カイロン コーポレイション | 抗原の粘膜送達のための生体接着剤およびアジュバントの使用 |
CN100392082C (zh) | 1999-04-30 | 2008-06-04 | 启龙股份公司 | 保守的奈瑟球菌抗原 |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
AU6226100A (en) * | 1999-07-19 | 2001-04-24 | Epimmune, Inc. | Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
ES2541830T3 (es) | 1999-10-29 | 2015-07-27 | Novartis Vaccines And Diagnositics S.R.L. | Péptidos antigénicos de Neisseria |
US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
ES2319727T3 (es) * | 1999-12-01 | 2009-05-12 | Novartis Vaccines And Diagnostics, Inc. | Estimulacion de anticuerpos especificos de hcv. |
PT1248647E (pt) | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b |
ES2317900T3 (es) | 2000-04-05 | 2009-05-01 | Schering Corporation | Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2. |
NZ521456A (en) | 2000-04-19 | 2004-07-30 | Schering Corp | Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
EP1829891B1 (en) * | 2000-06-15 | 2012-12-26 | Novartis Vaccines and Diagnostics, Inc. | Immunoassays for Anti-HCV Antibodies |
SI1354204T2 (sl) * | 2000-06-15 | 2010-09-30 | Novartis Vaccines & Diagnostic | Hcv antigen antitelo kombinacijska analiza |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
US7012066B2 (en) | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AU8063701A (en) | 2000-07-21 | 2002-02-05 | Schering Corp | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
CA2419418A1 (en) * | 2000-08-17 | 2002-02-21 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US6858590B2 (en) | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
EP2277895B1 (en) | 2000-10-27 | 2013-08-14 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
HUP0303436A2 (hu) | 2000-12-12 | 2004-01-28 | Schering Corp. | Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
US7196183B2 (en) | 2001-08-31 | 2007-03-27 | Innogenetics N.V. | Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
US20050106162A1 (en) | 2001-12-12 | 2005-05-19 | Guido Grandi | Immunisation against chlamydia trachomatis |
WO2003062228A1 (en) | 2002-01-23 | 2003-07-31 | Schering Corporation | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection |
CA2476626A1 (en) | 2002-02-20 | 2003-08-28 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
PT2014671E (pt) | 2002-03-11 | 2010-06-16 | Lab 21 Ltd | Métodos e composições para identificar e caracterizar a hepatite c |
US7598421B2 (en) | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
CA2485829A1 (en) | 2002-05-24 | 2003-12-04 | Peng Luan | Methods and constructs for high yield expression of clostripain |
EP1546414B1 (en) | 2002-09-09 | 2008-10-08 | Novartis Vaccines and Diagnostics, Inc. | Hcv assay |
US7115374B2 (en) | 2002-10-16 | 2006-10-03 | Gen-Probe Incorporated | Compositions and methods for detecting West Nile virus |
US7927840B2 (en) | 2006-09-11 | 2011-04-19 | Gen Probe Incorporated | Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region |
WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
WO2004084936A2 (en) | 2003-02-06 | 2004-10-07 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
ES2382332T3 (es) | 2003-02-06 | 2012-06-07 | Aduro Biotech | Listeria atenuada para entrar en células no fagocíticas, vacunas que comprenden esta listeria y métodos de uso de las mismas |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
US7449447B2 (en) | 2003-08-26 | 2008-11-11 | Schering Corporation | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus |
US8124747B2 (en) | 2003-08-29 | 2012-02-28 | Innogenetics | HCV clade and prototype sequences thereof |
CN102659922B (zh) | 2003-09-22 | 2013-11-06 | 株式会社绿多肽 | 来源于c型肝炎病毒的肽 |
BRPI0414814A (pt) | 2003-09-26 | 2006-11-14 | Schering Corp | inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c |
JP4584260B2 (ja) * | 2003-10-14 | 2010-11-17 | インターミューン・インコーポレーテッド | Hcv複製阻害剤としての大環状カルボン酸およびアシルスルホンアミド |
US7253160B2 (en) | 2003-11-20 | 2007-08-07 | Schering Corporation | Depeptidized inhibitors of hepatitis C virus NS3 protease |
US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
ATE438622T1 (de) | 2004-02-27 | 2009-08-15 | Schering Corp | 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
EP1939213B1 (en) | 2004-02-27 | 2010-08-25 | Schering Corporation | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease |
TW200602037A (en) | 2004-02-27 | 2006-01-16 | Schering Corp | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease |
KR20060124725A (ko) | 2004-02-27 | 2006-12-05 | 쉐링 코포레이션 | C형 간염 바이러스 ns3 프로테아제의 억제제 |
EP1773868B1 (en) | 2004-05-20 | 2009-07-15 | Schering Corporation | Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease |
EP1784211A4 (en) | 2004-07-29 | 2010-06-30 | Novartis Vaccines & Diagnostic | IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE |
ES2377978T3 (es) | 2004-08-27 | 2012-04-03 | Novartis Vaccines And Diagnostics, Inc. | Mutantes de proteínas no estructurales de VHC y usos de los mismos |
ATE513844T1 (de) | 2004-08-27 | 2011-07-15 | Schering Corp | Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
DK2399893T3 (en) | 2004-12-22 | 2018-10-08 | Ambrx Inc | COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES |
CA2605749C (en) | 2005-04-26 | 2015-06-30 | Eisai Co., Ltd. | Compositions and methods for cancer immunotherapy |
WO2007031867A2 (en) | 2005-05-25 | 2007-03-22 | Tripep Ab | A hepatitis c virus non-stru tural ns3/4a fusion gene |
PL1891089T3 (pl) | 2005-06-02 | 2015-05-29 | Merck Sharp & Dohme | Inhibitory proteazy HCV w połączeniu z pokarmem |
KR20080021634A (ko) | 2005-06-02 | 2008-03-07 | 쉐링 코포레이션 | 약제학적 조성물 및 이를 사용한 치료 방법 |
WO2007053245A2 (en) | 2005-09-20 | 2007-05-10 | Immunivest Corporation | Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes |
WO2007135707A1 (ja) | 2006-05-18 | 2007-11-29 | Nichia Corporation | 樹脂成形体及び表面実装型発光装置並びにそれらの製造方法 |
DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
SG10201605208QA (en) | 2007-11-07 | 2016-08-30 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
WO2009076158A1 (en) | 2007-12-07 | 2009-06-18 | Novartis Ag | Compositions for inducing immune responses |
NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
WO2009130588A2 (en) | 2008-04-22 | 2009-10-29 | Tripep Ab | Immunogen platform |
CN102076843A (zh) | 2008-05-19 | 2011-05-25 | 艾杜罗生物科技公司 | 包含prfa*突变体李斯特菌的组合物及其使用方法 |
KR101647164B1 (ko) | 2008-09-26 | 2016-08-09 | 암브룩스, 인코포레이티드 | 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도 |
TW201032801A (en) | 2008-12-12 | 2010-09-16 | Schering Corp | Deuterated compounds as hepatitis C virus (HCV) inhibitors |
WO2010103017A2 (en) | 2009-03-09 | 2010-09-16 | William Henry | Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions |
EP2435424B1 (en) | 2009-05-29 | 2015-01-21 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
AU2010324871A1 (en) | 2009-11-25 | 2012-06-14 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
EP2333074A1 (en) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
JP2013515068A (ja) | 2009-12-22 | 2013-05-02 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法 |
PL2528922T3 (pl) | 2010-01-27 | 2018-01-31 | Ab Pharma Ltd | Związki poliheterocykliczne jako inhibitory hcv |
KR20130008040A (ko) | 2010-03-09 | 2013-01-21 | 머크 샤프 앤드 돔 코포레이션 | 융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법 |
JP6002659B2 (ja) | 2010-04-13 | 2016-10-05 | セルデックス・セラピューティクス・インコーポレイテッド | ヒトcd27に結合する抗体およびその使用 |
MX343410B (es) | 2010-07-06 | 2016-11-04 | Novartis Ag * | Emulsiones cationicas de agua en aceite. |
EP2598149A4 (en) | 2010-07-26 | 2014-09-10 | Merck Sharp & Dohme | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES |
EP2621279B1 (en) | 2010-09-29 | 2018-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
JP6120839B2 (ja) | 2011-07-06 | 2017-04-26 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
EP3424495A1 (en) | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
EP2755981A4 (en) | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES |
BR112014008694A2 (pt) | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
DK3274478T3 (da) | 2015-03-27 | 2020-11-23 | Ortho Clinical Diagnostics K K | Hcv-ns4a/modificerede ns3-polypeptider og anvendelser deraf |
US10550379B2 (en) | 2015-06-29 | 2020-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
EA201892362A1 (ru) | 2016-04-18 | 2019-04-30 | Селлдекс Терапьютикс, Инк. | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464474A (en) * | 1980-07-09 | 1984-08-07 | Connaught Laboratories Limited | Non-A, non-B hepatitis assay and vaccine |
EP0071640B1 (en) * | 1981-02-11 | 1986-06-04 | Connaught Laboratories Incorporated | Non-a, non-b hepatitis virus |
US4702909A (en) * | 1982-05-05 | 1987-10-27 | Louisiana State University A & M | Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent |
US4673634A (en) * | 1985-03-08 | 1987-06-16 | The United States Of America As Represented By The Department Of Health And Human Services | Purified antigen from non-A, non-B hepatitis causing factor |
WO1987005930A1 (en) * | 1986-04-01 | 1987-10-08 | Genelabs Incorporated | Immortalized virus-specific tissue cells |
JPS6391328A (ja) * | 1986-10-07 | 1988-04-22 | Mitsubishi Kasei Corp | 非a非b型肝炎抗原 |
NZ222465A (en) * | 1986-11-07 | 1992-11-25 | Pasteur Institut | Nanb (non a, non b hepatitis viral) antigen |
DE3744242A1 (de) * | 1987-02-20 | 1989-07-06 | Seelig Renate | Virusantigen, verfahren zu seiner gewinnung und anwendung in diagnose und therapie (impfstoff) |
CN1074422C (zh) * | 1987-11-18 | 2001-11-07 | 希龙股份有限公司 | 制备含有hcv表位的分离多肽的方法 |
-
1988
- 1988-11-18 CN CN92110257A patent/CN1074422C/zh not_active Expired - Lifetime
- 1988-11-18 WO PCT/US1988/004125 patent/WO1989004669A1/en active Application Filing
- 1988-11-18 HU HU9502949A patent/HU220204B/hu unknown
- 1988-11-18 NZ NZ227011A patent/NZ227011A/en unknown
- 1988-11-18 CA CA583561A patent/CA1341629C/en active Active
- 1988-11-18 IE IE347288A patent/IE62868B1/en not_active IP Right Cessation
- 1988-11-18 BR BR888807310A patent/BR8807310A/pt not_active Application Discontinuation
- 1988-11-18 ES ES88310922T patent/ES2012739T5/es not_active Expired - Lifetime
- 1988-11-18 JP JP89500565A patent/JPH02500880A/ja not_active Expired - Lifetime
- 1988-11-18 HU HU388/89A patent/HU216017B/hu unknown
- 1988-11-18 UA UA4742221A patent/UA42668C2/uk unknown
- 1988-11-18 CN CN88107988A patent/CN1049686C/zh not_active Expired - Lifetime
- 1988-11-18 DE DE198888310922T patent/DE318216T1/de active Pending
- 1988-11-18 EP EP88310922A patent/EP0318216B2/en not_active Expired - Lifetime
- 1988-11-18 DE DE3886363T patent/DE3886363T3/de not_active Expired - Lifetime
- 1988-11-28 KR KR1019890701343A patent/KR0138776B1/ko not_active IP Right Cessation
-
1989
- 1989-07-17 FI FI893447A patent/FI105652B/fi not_active IP Right Cessation
- 1989-07-17 NO NO892931A patent/NO304990B1/no unknown
-
1991
- 1991-07-31 GR GR90300069T patent/GR900300069T1/el unknown
-
1992
- 1992-12-16 JP JP4361784A patent/JP2809956B2/ja not_active Expired - Lifetime
- 1992-12-16 JP JP4361785A patent/JP2662350B2/ja not_active Expired - Lifetime
- 1992-12-16 JP JP4361787A patent/JP2662351B2/ja not_active Expired - Lifetime
- 1992-12-16 JP JP4361786A patent/JP2532805B2/ja not_active Expired - Lifetime
-
1993
- 1993-04-22 HK HK382/93A patent/HK38293A/xx not_active IP Right Cessation
- 1993-05-31 LV LVP-93-440A patent/LV10726B/en unknown
- 1993-06-11 JP JP5178446A patent/JP2662358B2/ja not_active Expired - Lifetime
-
1995
- 1995-06-23 HU HU95P/P00427P patent/HU211905A9/hu unknown
-
1996
- 1996-08-21 JP JP8239921A patent/JP2810022B2/ja not_active Expired - Lifetime
- 1996-08-22 JP JP24145196A patent/JP3171793B2/ja not_active Expired - Lifetime
-
1997
- 1997-04-01 JP JP9099651A patent/JP2810032B2/ja not_active Expired - Lifetime
- 1997-07-22 KR KR1019970704975A patent/KR100216013B1/ko not_active IP Right Cessation
-
1998
- 1998-04-06 JP JP10111631A patent/JPH10290696A/ja active Pending
- 1998-04-06 JP JP10111632A patent/JPH10290697A/ja active Pending
- 1998-06-15 FI FI981380A patent/FI106564B/fi not_active IP Right Cessation
-
1999
- 1999-06-03 JP JP11157193A patent/JP2000023683A/ja active Pending
- 1999-07-01 CN CN99108969A patent/CN1129796C/zh not_active Expired - Lifetime
-
2000
- 2000-05-18 CN CNB001086987A patent/CN1159584C/zh not_active Expired - Lifetime
- 2000-05-18 CN CNB001089277A patent/CN100397082C/zh not_active Expired - Lifetime
- 2000-06-12 FI FI20001390A patent/FI107620B/fi not_active IP Right Cessation
- 2000-08-25 HK HK00105341A patent/HK1026023A1/xx not_active IP Right Cessation
-
2001
- 2001-06-20 HK HK01104275A patent/HK1033773A1/xx not_active IP Right Cessation
-
2005
- 2005-11-09 JP JP2005325483A patent/JP2006104207A/ja not_active Withdrawn
- 2005-11-09 JP JP2005325486A patent/JP2006117681A/ja not_active Withdrawn
-
2007
- 2007-03-30 JP JP2007095590A patent/JP2007197456A/ja active Pending
- 2007-07-06 JP JP2007179093A patent/JP2008007508A/ja active Pending
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714596A (en) * | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
US6861212B1 (en) | 1987-11-18 | 2005-03-01 | Chiron Corporation | NANBV diagnostics and vaccines |
US6171782B1 (en) | 1987-11-18 | 2001-01-09 | Chiron Corporation | Antibody compositions to HCV and uses thereof |
US6096541A (en) * | 1987-11-18 | 2000-08-01 | Chiron Corporation | Cell culture systems for HCV |
US6074816A (en) * | 1987-11-18 | 2000-06-13 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
US5712088A (en) * | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
JPH03139282A (ja) * | 1988-09-30 | 1991-06-13 | Handai Biseibutsubiyou Kenkyukai | 非a非b肝炎患者の血清と抗原抗体反応するペプチド、及び該ペプチドをコードするdna |
US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
JP2733138B2 (ja) * | 1990-04-04 | 1998-03-30 | カイロン コーポレイション | 抗hcv抗体の免疫アッセイに使用するc型肝炎ウイルス(hcv)抗原の組合せ |
US5734019A (en) * | 1990-06-12 | 1998-03-31 | National Institute Of Health | Hepatitis C virus antigen polypeptide, production method therefor, and antibody detection method |
US5714314A (en) * | 1990-06-12 | 1998-02-03 | National Institute Of Health | Hepatitis C virus antigen polypeptide, production method therefor, and antibody detection method |
WO1991019744A1 (en) * | 1990-06-12 | 1991-12-26 | Japan As Represented By Director General Of Agency Of National Institute Of Health | Hepatitis c virus antigen polypeptide, production thereof, and detection of antibody |
WO1992001714A1 (en) * | 1990-07-24 | 1992-02-06 | Yamanouchi Pharmaceutical Co., Ltd. | Non-a non-b hepatitis virus antigen |
WO1992009634A1 (en) * | 1990-11-29 | 1992-06-11 | Toray Industries, Incorporated | Non-a non-b hepatitis virus antigen protein |
WO1992018532A1 (en) * | 1991-04-17 | 1992-10-29 | Eisai Co., Ltd. | Rna, dna and virus antigen protein of non-a non-b hepatitis virus |
JPH06153959A (ja) * | 1992-10-16 | 1994-06-03 | Evernew Biotec Inc | C型肝炎ウィルスの非構造タンパク質及びそれを用いての診断方法及びキット |
EP0717104A2 (en) | 1994-07-12 | 1996-06-19 | The Tokyo Metropolitan Institute Of Medical Science | Immunoassay of non-A, non-B hepatitis virus-related antigens, monoclonal antibodies for use therein, and hybridomas producing the antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH02500880A (ja) | Nanbvの診断用薬およびワクチン | |
US5698390A (en) | Hepatitis C immunoassays | |
US5350671A (en) | HCV immunoassays employing C domain antigens | |
US6346375B1 (en) | NANBV diagnostics and vaccines | |
US6027729A (en) | NANBV Diagnostics and vaccines | |
US6171782B1 (en) | Antibody compositions to HCV and uses thereof | |
GB2212511A (en) | Hepatitis C virus | |
AU624105B2 (en) | Nanbv diagnostics and vaccines | |
US6861212B1 (en) | NANBV diagnostics and vaccines | |
AU624105C (en) | NANBV diagnostics and vaccines | |
DK176280B1 (da) | NANBV-diagnostika og -vacciner | |
HRP940493A2 (en) | Nanbv diagnostics and vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071115 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081115 Year of fee payment: 15 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091115 Year of fee payment: 16 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091115 Year of fee payment: 16 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091115 Year of fee payment: 16 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091115 Year of fee payment: 16 |